ClinicalTrials.gg
RecruitingNCT07293715PRISMUpdated Nov 9, 2026

Permissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM)

A Phase 4 interventional study of Insulin and DEXCOM Continuous Glucose Monitor in Pregnancy, High Risk, Type 1 Diabetes and Type 2 Diabetes, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Ohio State University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Nov 9, 2026Eligibility revisedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing insulin in Diabetes Mellitus, Type 1 — 4 open to participants now, 4 under way, none of them phase 3. Insulin · Diabetes Mellitus, Type 1.

Planned enrollment
14th of 51
44 · median 20
Started
2026
with 1 other
Phase 4
10 of 51
3 open now
Registered
50th of 51
by date

Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, this one is the 14th largest by planned enrollment, is one of 2 that started in 2026, is one of 10 in phase 4, and was the 50th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 51 studies testing insulin in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

PRISM is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with pregestational diabetes using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.

Read the detailed description

The incidence of pregestational diabetes in pregnancy, including Type 1 Diabetes and Type 2 Diabetes is currently estimated at 1%. Infants born to individuals with pregestational diabetes are at increased risk of adverse pregnancy outcomes due to lack of glycemic control. Individuals with T1D are increasingly using hybrid closed loop therapy (HCL) for insulin delivery to achieve glycemic control. Current data highlight that less permissive intrapartum (while in labor) glycemic control is not associated with a increased risk of adverse pregnancy outcomes, including neonatal hypoglycemia and NICU admission. However, such data about permissive versus strict intrapartum glucose management has primarily been from pregnant individuals with type 2 diabetes or gestational diabetes who did not use HCL based insulin therapy. Pregnant individuals with diabetes who use HCL with continuous glucose monitoring and closed loop insulin delivery represent a unique population, and data from this population are needed to inform intrapartum obstetric management. The investigators hypothesize that permissive intrapartum glucose management using continuous glucose monitoring (70-140 mg/dL) will not be associated with neonatal dysglycemia measured as first mean neonatal glucose value within the first two hours of life compared with strict intrapartum glucose management or the current standard of care (70-110 mg/dL). The investigators will conduct a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with T1D using HCL who are admitted for labor management. The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia (first neonatal blood glucose measured within 2 hours of life) compared with strict intrapartum glucose management. The investigators will secondarily examine the association between permissive versus strict intrapartum glucose with adverse neonatal outcomes, including neonatal hypoglycemia, neonatal hyperbilirubinemia, and NICU admission, patient satisfaction, and continuous glucose monitor (CGM) metrics.

03

Conditions studied

  • Pregnancy, High Risk
  • Type 1 Diabetes
  • Type 2 Diabetes

Keywords

  • Pregnancy
  • Continuous Glucose Monitor
  • Type 1 Diabetes
  • Automated insulin delivery
  • Hybrid closed loop
  • Insulin pump
  • Type 2 Diabetes
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant individuals
  • ≥ 18 years old
  • Type 1 and Type 2 diabetes
  • Intention for vaginal delivery and admitted to Labor and Delivery
  • Singleton, non-anomalous fetus
  • Gestational age greater than or equal to 35 weeks gestation.
  • Cervical dilation is less than 6 cm.
  • Delivering at the study institution

Exclusion criteria

Exclusion criteria:

  • Scheduled cesarean delivery
  • Cervical dilation ≥ 6 cm on presentation to L\&D
  • Receipt of antenatal within 7 days of randomization
  • Fetal demise
  • Major fetal anomaly (attached)
  • Multiple gestation
  • Non-English speaking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Intervention group

    permissive blood sugar control (70-140 mg/dL)

    Drug: Insulin · Device: DEXCOM Continuous Glucose Monitor

  • Other
    Standard of care

    strict blood sugar control (70-110 mg/dL)

    Drug: Insulin · Device: DEXCOM Continuous Glucose Monitor

Interventions

  • Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). Participants and clinicians will be unblinded. Once randomized, an order set will be entered into the EMR that will alert pharmacy and nursing colleagues to the appropriate intrapartum glycemic control protocol.

  • DeviceDEXCOM Continuous Glucose Monitor

    Patients will be asked to wear an optional Continuous Glucose Monitor (CGM) to utilize during labor for research purposes. The CGM will be removed prior to hospital discharge and data will be extracted by trained research personnel. All participants already utilize a CGM device as part of standard of care as part of Hybrid Closed Loop (HCL) therapy. No clinical decisions will be made based upon data from the research CGM device. This data will not be extracted until after hospital discharge.

06

What researchers measure

Primary outcomes

  1. Mean of first neonatal blood glucose (continuous, mean with standard deviation)

    The first heel stick neonatal blood glucose (mg/dL) will be obtained within the first two hours of life utilizing a hospital-grade glucometer. This will be recorded in the electronic medical record and abstracted at study conclusion. The mean of these will be utilized as the primary outcome. A heel stick neonatal blood glucose in the first two hours of life is current standard of care for all infants of diabetic individuals.

    Time frame: From birth to 2 hours after birth

Secondary outcomes

  1. Neonatal C-peptide (continuous, mean with standard deviation)

    Umbilical cord C-peptide levels will be analyzed from cord blood collected at the time of delivery.

    Time frame: At birth

  2. Neonatal hypoglycemia

    Neonatal hypoglycemia: blood glucose \< 40mg/dl in birth to 4 hours of life, \< 45mg/dl in 4-24 hours of life, and \< 50mg/dl after 24 hours of life, or need for oral or IV glucose therapy.

    Time frame: At birth, up to 24 hours

  3. Neonatal hyperbilirubinemia

    Neonatal jaundice requiring phototherapy

    Time frame: Within the first 48 hours after birth

  4. NICU admission

    Admitted to NICU during delivery admission

    Time frame: Within the first 48 hours after birth

  5. Birth experience satisfaction per Birth Satisfaction Survey-Revised (BSS-R) (continuous, mean with standard deviation)

    The Birth Satisfaction Survey-Revised (BSS-R) is a validated patient satisfaction survey describing L\&D birthing experiences. This survey will be administered at any time during their postpartum admission. This measure will be analyzed as a continuous mean score.

    Time frame: Day 1 through study completion (at hospital discharge), up to 4 weeks

  6. Maternal IV insulin maximum dose and duration

    Maternal IV insulin maximum IV insulin dose (units) and duration (hours) will be measured as continuous variables (mean and SD).

    Time frame: Day 1 through study completion, up to 4 weeks

  7. Maternal Hypoglycemia

    Maternal blood glucose less than 70 mg/dL, as measured by capillary blood glucose via hospital-grade glucometer.

    Time frame: Day 1 through study completion, up to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 62 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 16 months is below that.

Counting every sponsor, half of 74 studies reached it within 22 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 19, 2025
StartActual
Feb 25, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedType 1 and Type 2 diabetes
Nov 9, 2026
Title
Permissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM-T1D)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedType 1 and Type 2 diabetes
    Title Permissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM-T1D)
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07293715
Responsible party
Kartik K Venkatesh (Principal Investigator, Ohio State University) — Principal investigator
First posted
Dec 19, 2025
Start date
Feb 25, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Anna Brewton, MD
Contact
Anna.Brewton@osumc.edu
614-293-8045
Anna Brewton, MD
principal investigator · Ohio State University
Kartik K Venkatesh, MD, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion